We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00225095
Recruitment Status : Completed
First Posted : September 23, 2005
Last Update Posted : December 4, 2014
Information provided by (Responsible Party):

September 21, 2005
September 23, 2005
December 4, 2014
September 2005
April 2008   (Final data collection date for primary outcome measure)
meniscal volume [ Time Frame: 6 months ]
  • meniscal volume
  • adverse events
Complete list of historical versions of study NCT00225095 on ClinicalTrials.gov Archive Site
  • quality of life [ Time Frame: 2 years ]
  • immunological endpoints [ Time Frame: Baseline to 2 years ]
  • Safety [ Time Frame: 2 years ]
  • quality of life
  • immunological endpoints
Not Provided
Not Provided
A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy
A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years
The purpose of this study is to determine whether Chondrogen is a safe and effective post-operative treatment of the knee following menisectomy (the surgical removal of all or part of a torn meniscus).

Chondrogen is a preparation of adult mesenchymal stem cells (MSCs) in a solution containing hyaluronic acid. Preclinical studies have shown that injection of Chondrogen aids in the repair of meniscal tissue following meniscectomy. In Chondrogen treated subjects, surgically removed meniscal tissue was regenerated, cartilage surface was protected, and joint damage was decreased in comparison to control subjects. These benefits persisted at least one year.

Three groups of recent meniscectomy patients will be followed in this study, including patients that will receive placebo and patients that will be treated with one of two possible doses of Chondrogen.

Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Recovery Following Partial Medial Meniscectomy
  • Drug: Mesenchymal Stem Cells
  • Drug: Hyaluronan
  • Active Comparator: Arm 1
    Chondrogen dose 1
    Intervention: Drug: Mesenchymal Stem Cells
  • Active Comparator: Arm 2
    Chondrogen dose 2
    Intervention: Drug: Mesenchymal Stem Cells
  • Active Comparator: Arm 3
    Intervention: Drug: Hyaluronan

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 to 60, inclusive
  • In need of medial meniscectomy
  • Normal axial alignment
  • Stable knee- previous ligament reconstruction, if stable
  • Removal of at least 50% of the affected portion of the medial meniscus
  • Intact articular cartilage in posterior meniscal weight-bearing zone
  • Willingness to follow normal post-operative rehabilitation
  • Willingness to participate in follow-up for two years from the time of meniscectomy surgery
  • Ability to understand and willingness to sign consent form

Exclusion Criteria:

  • Pregnant or lactating
  • ACL or other support structure damage confirmed at surgery
  • Grade III or IV cartilage damage (Cartilage loss greater than 50% thickness in area >15mm on weight-bearing aspect of femoral condyle or tibial plateau)
  • Synvisc, steroid, or corticosteroid injections in preceding 3 months
  • Diffuse synovitis at time of arthroscopy
  • Inflammatory arthritis
  • Oral steroid, methotrexate therapy
  • Unable to follow post-operative exercise regimen or return for evaluations
  • Active alcohol or substance abuse within 6 months of study entry
  • Current and active tobacco product use
  • Patient is positive for HIV
  • Patient is positive for hepatitis (past history of Hepatitis A is allowed)
  • Any medical condition, which in the opinion of the clinical investigator, would interfere with the treatment or outcome of the patient
  • Indwelling pacemaker
  • Cerebral aneurysm clips
  • Ear, eye and penile implants with avian components
  • Electrical indwelling device such as bone stimulator
  • Indwelling magnets as tissue expander for future implants
  • Known allergy to avian, bovine or porcine protein
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Osiris 550
Not Provided
Not Provided
Not Provided
Mesoblast, Ltd. ( Mesoblast International Sàrl )
Mesoblast International Sàrl
  • University of Southern California
  • Midwest Orthopedics at Rush - Chicago, IL
  • Unlimited Research - San Antonio, TX
  • Triangle Orthopaedic Associates, P.A.
  • Orthopedic Center of Vero Beach - Vero Beach, FL
  • OrthoIndy
  • TRIA Orthopaedic Center
  • Greater Chesapeake Associates - Baltimore, MD
Study Director: Michelle Williams, Ph.D. Osiris Therapeutics, Inc.
Mesoblast, Ltd.
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP